Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Purchased by Versor Investments LP

Versor Investments LP boosted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 36.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,582 shares of the specialty pharmaceutical company’s stock after buying an additional 5,200 shares during the quarter. Versor Investments LP’s holdings in Collegium Pharmaceutical were worth $561,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sanctuary Advisors LLC raised its position in Collegium Pharmaceutical by 5.3% in the 4th quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company’s stock valued at $542,000 after purchasing an additional 952 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Collegium Pharmaceutical by 5.8% during the fourth quarter. Rhumbline Advisers now owns 108,228 shares of the specialty pharmaceutical company’s stock worth $3,101,000 after buying an additional 5,920 shares during the period. Meritage Portfolio Management increased its stake in shares of Collegium Pharmaceutical by 5.0% during the fourth quarter. Meritage Portfolio Management now owns 20,755 shares of the specialty pharmaceutical company’s stock worth $595,000 after buying an additional 979 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after acquiring an additional 642 shares in the last quarter. Finally, Caprock Group LLC lifted its stake in Collegium Pharmaceutical by 6.7% in the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company’s stock worth $249,000 after acquiring an additional 543 shares during the last quarter.

Collegium Pharmaceutical Trading Up 2.2 %

Shares of Collegium Pharmaceutical stock opened at $29.05 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company has a fifty day simple moving average of $30.82 and a 200-day simple moving average of $33.47. The stock has a market cap of $936.86 million, a price-to-earnings ratio of 12.52 and a beta of 0.82. Collegium Pharmaceutical, Inc. has a 12-month low of $27.84 and a 12-month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. On average, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on COLL. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Piper Sandler dropped their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. Finally, Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $43.60.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares of the company’s stock, valued at $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.